Rishi R. Goel,Mark M. Painter,Sokratis A. Apostolidis,Divij Mathew,Wenzhao Meng,Aaron M. Rosenfeld,Kendall A. Lundgreen,Arnold Reynaldi,David S. Khoury,Ajinkya Pattekar,Sigrid Gouma,Leticia Kuri-Cervantes,Philip Hicks,Sarah Dysinger,Amanda Hicks,Harsh Sharma,Sarah Herring,Scott Korte,Amy E. Baxter,Derek A. Oldridge,Josephine R. Giles,Madison E. Weirick,Christopher M. McAllister,Moses Awofolaju,Nicole Tanenbaum,Elizabeth M. Drapeau,Jeanette Dougherty,Sherea Long,Kurt D’Andrea,Jacob T. Hamilton,Maura McLaughlin,Justine C. Williams,Sharon Adamski,Oliva Kuthuru,Ian Frank,Michael R. Betts,Laura A. Vella,Alba Grifoni,Daniela Weiskopf,Alessandro Sette,Scott E. Hensley,Miles P. Davenport,Paul Bates,Eline T. Luning Prak,Allison R. Greenplate,E. John Wherry,

Abstract:ABSTRACT SARS-CoV-2 mRNA vaccines have shown remarkable efficacy, especially in preventing severe illness and hospitalization. However, the emergence of several variants of concern and reports of declining antibody levels have raised uncertainty about the durability of immune memory following vaccination. In this study, we longitudinally profiled both antibody and cellular immune responses in SARS-CoV-2 naïve and recovered individuals from pre-vaccine baseline to 6 months post-mRNA vaccination. Antibody and neutralizing titers decayed from peak levels but remained detectable in all subjects at 6 months post-vaccination. Functional memory B cell responses, including those specific for the receptor binding domain (RBD) of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants, were also efficiently generated by mRNA vaccination and continued to increase in frequency between 3 and 6 months post-vaccination. Notably, most memory B cells induced by mRNA vaccines were capable of cross-binding variants of concern, and B cell receptor sequencing revealed significantly more hypermutation in these RBD variant-binding clones compared to clones that exclusively bound wild-type RBD. Moreover, the percent of variant cross-binding memory B cells was higher in vaccinees than individuals who recovered from mild COVID-19. mRNA vaccination also generated antigen-specific CD8+ T cells and durable memory CD4+ T cells in most individuals, with early CD4+ T cell responses correlating with humoral immunity at later timepoints. These findings demonstrate robust, multi-component humoral and cellular immune memory to SARS-CoV-2 and current variants of concern for at least 6 months after mRNA vaccination. Finally, we observed that boosting of pre-existing immunity with mRNA vaccination in SARS-CoV-2 recovered individuals primarily increased antibody responses in the short-term without significantly altering antibody decay rates or long-term B and T cell memory. Together, this study provides insights into the generation and evolution of vaccine-induced immunity to SARS-CoV-2, including variants of concern, and has implications for future booster strategies. GRAPHICAL ABSTRACT

Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues

Innate Immune Memory Of Tissue-Resident Macrophages And Trained Innate Immunity: Re-Vamping Vaccine Concept And Strategies

Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and is Critical to Trained Immunity

Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine

The use of semantic knowledge in Alzheimer's disease: Evidence for impairments of attention

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection

Molecular regulation of effector and memory T cell differentiation

The immune memory of innate immune systems

Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination

Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination

mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern

Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection

Vaccination against rapidly evolving pathogens and the entanglements of memory

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines

Immune recall improves antibody durability and breadth to SARS-CoV-2 variants

[Neuromuscular effects of cisatracurium besylate in obese patients].

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19